The so-called "post-genome era" is nearly upon us, at least in terms of the human genome. With their genomes among the first to be sequenced, such status has been in effect for several years for the fruit fly Drosophila melanogaster, the worm Caenorhabditis elegans, several species of bacteria, and some plant species such as Arabidopsis. What does the availability of the human genome sequence, and the tools to use it, mean in terms of basic and clinical research aimed at understanding and treating common malignancies such as prostate carcinoma?
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Misconceptions as to what the basic information encoded by the human genome will or will not allow molecular biologists, epidemiologists, geneticists, and clinicians to do in the immediate time frame abound. In this presentation, we discuss some of these issues as well as summarize the recent technical advances that are likely to change the way we do science in the coming decade.
In a very practical sense, the sequence of the human genome can be thought of as a blueprint or set of ordered instructions that requires interpretation using a sophisticated set of rules. As with many languages, the words in the instruction set are heavily context-dependent and may be interpreted with wide latitude. We have a reasonably good idea of the constraints dictated by some parts of the instructions (e.g., three base pairs form a codon, which in turn specifies the amino acid), but other constraints, such as mechanisms of transcriptional regulation which regulate the messenger RNA (mRNA) level and turnover remain poorly understood. It is safe to say that we are still learning the rules for interpretation, and as we begin to understand the syntax more precisely, we can expect to gain further insight as to how the genome and its dynamic output, the proteome, causes disease.
Acquiring and interpreting data in such large dimensions has been aided by the development of biotechnologic tools such as automated DNA sequencers, DNA arrays, and corn-putational algorithms designed to assemble and interpret genome-wide mapping studies. At this juncture, the most valuable asset is clearly the human genome sequence, a first draft of which was completed in 2000. A listing of the ordered set of bases encoded on human chromosomes provides researchers with a listing of the genes and regulatory motifs that enable scientific questions to be addressed by experimentation in a rapid and comprehensive fashion. Indeed, the complete genome sequence facilitates biomedical investigations in at least three fundamental ways: First, the sequence greatly expedites access to basic reagents such as gene primers for polymerase chain reaction-based analysis of single genes, gene probes for performing gene expression studies, and genetic variations (simple sequence repeats (SSRs), single-nucleotide polymorphisms (SNPs)) suitable for mapping and association studies. Previously, the acquisition of these reagents could take weeks to months, and they are now accessible with the click(s) of a mouse button. It is important to realize, however, that of course any given SNP map not be informative in a pedigree of interest, and large numbers of SNPs are likely needed to map disease genes in any outbred population. Second, the knowledge and availability of all genes allows for systematic and comprehensive studies to be performed. This greatly enhances the ability to determine the interrelations of gene networks and pathways that interact and influence a cellular state, rather than studying individual genes in isolation. This information should also allow for the study of traits that are polygenic and/or are influenced by environmental exposures. These technologies, however, are no substitute for collecting clinical and family history data which will allow us to stratify large collections families with complex diseases, such as cancer and heart disease, by features which promote the development of homogenous data sets, thus simplifying issues associated with locus heterogeneity. Third, the human genome sequence and corresponding genome map allows for rapid follow-up of genetic studies that localize a trait to a specific region of the genome by providing a complete list of candidate genes for mutation screening. Previously, positional cloning was a time-consuming and laborious task that involved constructing physical maps spanning regions of interest, and then scanning the resulting bacterial artificial chromosomes (BACs) or yeast artificial chromosomes (YACs) for the coding sequences of all genes in the region. This information was subsequently used to assemble the full length sequence of all genes in the region, and then DNA from affected individuals was scanned for mutations. Finally, in addition to these three applications of broad utility, the genome sequence also facilitates studies of molecular evolution, cross species comparisons, and studies designed to assess gene function, also known as functional genomics.
Prostate cancer is, in many respects, an ideal disease on which to apply genome-based analysis. This realization has come about, in part, because of a consensus arrived at by geneticists, epidemiologists, and clinical scientists that progress in understanding prostate carcinogenesis using "traditional" tools of molecular biology and epidemiology has been limited. Despite the fact that prostate cancer is the most common cancer diagnosed in men, the underlying etiologic factors for the disease remain unclear. Studies to date have repeatedly emphasized the profound heterogeneity of prostate cancers in terms of hereditary influences, somatic genetic changes, racial variation, dietary influences, rates of disease initiation and progression, and treatment responses. Yet, patients are often treated uniformly using only limited clinical information as a guide. A genomics view may be the best hope for understanding the heterogenous nature of this disease. Ideally, new genomics-based investigations will lead to better diagnostics and prognostics, and could ultimately provide formulas for stratifying groups of individuals based on risk profiles in a way that dictates the best intervention. Given the strength and reliability with which we expect, or at least hope, predictions can be made, the gradient of such interventions is large and may range from simple observation to prophylactic treatment prior to any manifestation of disease. Ultimately such knowledge may lead to innovative approaches to prostate cancer prevention.
An area in which genomics-based approaches for the study of prostate cancer have already become evident is in mapping studies in which several different strategies come together to identify the genes and molecular mechanisms that make individuals unusually susceptible to disease. One approach involves linkage studies of germ-line DNA from patients with putatively inherited prostate cancer to identify genetic mutations or polymorphisms that correlate with the development of disease in high-risk families. These studies are truly genome-wide as markers spanning the entire genome are used in a systematic analysis of inheritance and disease incidence. Such studies have defined several prostate cancer loci to date (1) (2) (3) (4) (5) , but the relative strength of each result apparently depends on the methods by which the individual data sets of high-risk families are stratified (i.e., age at diagnosis, clinical features of disease, number of affected men per family) (6-11). Currently, it seems unlikely that there will be a prostate cancer counterpart to the breast cancer susceptibility genes BRCA1 or BRCA2 which accounts for the majority of inherited disease risk. Rather, there are likely to be a number of genes, some of which may interact with each other or with environmental exposures or other components of the genetic background, that contribute to disease. The differential importance of each gene mapped to date in unique data sets of seemingly similar families argues that, like sporadic disease, inherited prostate cancer is heterogeneous.
As prostate cancer susceptibility genes are located, genechip analysis or other rapidly advancing technologies such as mass spectrometry will be used for mutation detection. This will be particularly applicable to those cases in which disease-causing mutations can occur at several possible locations within the gene. Arrays and other technologies capable of high-throughput multiplex sequence analyses can be expected to play an increasingly important role in understanding the genetic nature of disease; indeed, they will likely be the next genotyping tool. SNPs offer a powerful way to identify genes contributing to polygenic traits, and thousands of these SNPs can be simultaneously detected on genotyping oligonucleotide chips. The tremendous amounts of information generated by these "laboratories-on-a-chip" will necessitate a continued revolution in the way scientists and physicians analyze and interpret data.
Given the enormous amount of information that is locked within the human genome sequence that will be made available from chip-based experiments such as those described above, it is encouraging that technology derived from the computer industry continues to drive the evolution of genome-wide expression studies. Combining the process of photolithography with solid-phase chemical synthesis yielded a method for building hundreds of thousands of oligonucleotides on a silicon wafer or gene chip (12) . Highly accurate robotic tools have been developed for spotting complementary DNA (cDNA) molecules onto glass slides (13) . Concepts adapted from ink-jet printers now allow for customized array construction. These oligonucleotide and cDNA chips can be hybridized with complex fluorescent probes and analyzed using high-resolution, high-sensitivity detectors. These systems have the ability to assess the expression of tens of thousands of genes, or tens of thousands of individuals for a single gene, simultaneously and with great reproducibility.
Genome-wide technologies have also been developed for the study of gene expression that might be influenced by DNA rearrangements, amplifications, or mutations in specific tumor-promoting or tumor-suppressing genes. We expect that correlating an expression profile with a pathologic condition will lead to development of rapid diagnostic tests and a means to further classify disease based upon molecular pathology (figure 1). To provide functional specificity to any given cell type, only a subset of the entire genome is expressed at any particular point in time. This fraction is estimated to be 10,000 to 30,000 unique transcribed genes (14) . Analogous to the genome, this "transcriptome" of expressed genes can be defined using methods to collect and identify all the mRNA molecules transcribed at a specific time point or cell state. The mRNA is converted to the more stable cDNA form and then partially sequenced in order to identify that message as a known gene, a sequence similar to a known gene, or a gene with uncharacterized function. This partial sequence of a cDNA clone represents a unique identifier called an expressed sequence tag (EST) or serial analysis of gene expression (SAGE) tag" (15, 16) . Clustering and annotating these gene tags into groups of related genes then defines the transcriptome for a given cell or tissue type, and allows for comprehensive comparisons of transcriptomes from different tissues. The hypothesis underlying this approach is that a normal cell uses or expresses a different portion of the genome, or expresses different genes at different levels, when compared to a neoplastic cellular counterpart. The qualitative and quan- titative changes in gene expression between the two cell states serve to identify specific genes and gene networks or pathways that are involved in the process of carcinogenesis. This type of detailed analysis, whereby biologic networks and pathways of chemical response are deciphered, may then identify specific molecular rearrangements that contribute to disease pathogenesis and thus identify potential targets for therapeutic intervention. As comprehensive studies of prostate cancer gene expression are undertaken using array-based approaches and studies of the corresponding proteome, success requires extensive input from pathologists, epidemiologists, and clinicians. In order to determine the significance of a cancer gene expression profile, the behavior or clinical outcome of the patient from which the tumor originated will need to be determined. Similarly, great care must be taken to obtain an accurate histologic profile of the starting tissue material. It is anticipated that a tumor gene expression profile will ultimately be used as a surrogate marker or determinant of disease risk or disease phenotype. The complexity and heterogeneity of prostate cancer will necessitate the study of hundreds to thousands of prostate tumors or patient samples. Understanding the implications of dietary and other environmental factors will similarly require large patient populations. This convergence of epidemiology, molecular biology, and genomics holds great promise for defining the pathogenesis of prostate carcinogenesis, and the interplay of these disciplines will be essential for significant scientific advances in the post-genome era.
A fundamental problem with the accumulation of vast amounts of molecular epidemiologic data, however, is that there is a risk that a tremendous amount of information will be assembled with little categorization, structure, data validation, or mechanisms for clinical correlations. There are as yet few standards for array-based expression studies in terms of replicate measurements, methodological error analysis, expected gene expression variance in normal individuals, gene expression variance as a result of co-existing disease states, etc. One particular danger is that poorly characterized and validated gene expression data will lower the sensitivity and specificity of comprehensive molecular assays and thus reduce utility of the data. In addition, the lack of common data-storage and data-sharing formats limit the widespread dissemination and use of gene expression data across populations and between investigators. However, these problems are well recognized by the field, and investigators using these tools are beginning to attempt standardization.
It appears that the key to understanding human health and disease may be found in the blueprint that is stored within each cell of the human body as the digital DNA code comprising the human genome. An understanding for how this information is stored, replicated, and processed has the potential to identify the basic mechanisms that underlie the development and progression of prostate cancer. While great advances have been achieved by investigators studying individual molecules involved in cancer development, the work has been hampered by the lack of a complete vocabulary of all potential molecules that are relevant for understanding and defining the cancer process. The completion of the Human Genome Project and the assembly of a virtual and physical prostate transcriptome will provide these resources in a readily accessible format suitable for both small and large-scale experimental applications regarding prostate cancer genetics and epidemiology. As methods have now been developed which permit the examination of genes and their cognate proteins in exquisite detail, biomedical sciences now have in hand the tools to begin comprehensive examination of the complex molecular events that occur in normal and cancerous prostate cells.
